Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
N
NNVC
vs
S&P 500
S&P 500
Over the past 12 months, NNVC has underperformed S&P 500, delivering a return of -4% compared to S&P 500's +17% growth.
Stocks Performance
NNVC vs S&P 500
Performance Gap
NNVC vs S&P 500
Performance By Year
NNVC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
NanoViricides Inc
Glance View
NanoViricides is a biotechnology company that tries to build antiviral drugs using a nanoparticle-based approach. Its core idea is to create drug candidates that can bind to viruses and block them from entering or infecting human cells. The company is still in the development stage, so it does not sell a broad line of commercial medicines; instead, it focuses on research, testing, and advancing drug candidates toward approval. The company’s main customers are not patients directly but the larger healthcare system that would use an approved antiviral drug, such as hospitals, doctors, and pharmacies. For now, NanoViricides makes money mainly through research and development funding, licensing or collaboration arrangements if they occur, and potentially future drug sales if any candidate reaches the market. Its value chain role is unusual because it is not a traditional large drug maker; it is more of a specialist developer trying to turn a platform idea into targeted antiviral medicines. What makes the business different is that it is focused on a single scientific concept: designing nanomedicines to fight viruses rather than using the standard small-molecule or biologic drug paths. That makes the company highly dependent on scientific results, regulatory progress, and funding. In plain terms, NanoViricides is a drug-development bet on a new way to attack viral infections.